{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-003906","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2023-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.339315+00:00","generated_at":"2026-06-20T12:26:03.990673+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Silo Pharma transmits three PCT patent applications to USPTO for psilocybin delivery","bullets":["Received notice of successful transmission to USPTO for three PCT patent applications.","Applications filed July 2021 relate to CNS-homing peptides delivering anti-inflammatory therapeutics with psilocybin.","National phase entries for these PCT applications are now at the USPTO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-003906","json":"https://secwatch.observer/filing/0001213900-23-003906.json","markdown":"https://secwatch.observer/filing/0001213900-23-003906.md","text":"https://secwatch.observer/filing/0001213900-23-003906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023003906/0001213900-23-003906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023003906/ea171925-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:26:03.990673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}